In last trading session, VBI Vaccines Inc. (NASDAQ:VBIV) saw 6,595,754 shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $2.65 trading at -$0.12 or -4.33% at ring of the bell on the day assigns it a market valuation of $641.44 Million. That closing price of VBIV’s stock is at a discount of -161.51% from its 52-week high price of $6.93 and is indicating a premium of 77.26% from its 52-week low price of $0.6025. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 8.21 Million shares which gives us an average trading volume of 9.55 Million if we extend that period to 3-months.
For VBI Vaccines Inc. (VBIV), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.5. Splitting up the data highlights that, out of 4 analysts covering the stock, none rated the stock as a Sell while 1 recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 3 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.22 in the current quarter.
VBI Vaccines Inc. (NASDAQ:VBIV) trade information
In the face of being in the red today for losing -4.33%, in the last five days VBIV remained trading in the green while hitting it’s week-highest on Wednesday, Nov 18 when the stock touched $3.02-1 price level, adding 12.19% to its value on the day. VBI Vaccines Inc.’s shares saw a change of 92.03% in year-to-date performance and have moved 8.61% in past 5-day. VBI Vaccines Inc. (NASDAQ:VBIV) showed a performance of -3.99% in past 30-days. Number of shares sold short was 42.65 Million shares which calculate 4.47 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $6.5 to the stock, which implies a rise of 145.28% to its current value. Analysts have been projecting $3 as a low price target for the stock while placing it at a high target of $9. It follows that stock’s current price would jump +239.62% in reaching the projected high whereas dropping to the targeted low would mean a loss of 13.21% for stock’s current value.
VBI Vaccines Inc. (VBIV) estimates and forecasts
Statistics highlight that VBI Vaccines Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added +7.72% of value to its shares in past 6 months, showing an annual growth rate of -54.35% while that of industry is 14.4. Apart from that, the company came raising its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to increase by 8.3% in the current quarter and calculating -5% decline in the next quarter. This year revenue growth is estimated to rise 4% from the last financial year’s standing.
1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $200Million for the same. And 1 analysts are in estimates of company making revenue of $200Million in the next quarter that will end in December 01, 2018. Company posted $193Million and $201Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 3.6% while estimating it to be -0.5% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 0% while estimates for its earnings growth in next 5 years are of 0%
VBI Vaccines Inc. (NASDAQ:VBIV)’s Major holders
Insiders are in possession of 3.52% of company’s total shares while institution are holding 57.75% percent of that, with stock having share float percentage of 59.86%. Investors also watch the number of corporate investors in a company very closely, which is 149 institutions for VBI Vaccines Inc. that are currently holding shares of the company. Perceptive Advisors Llc is the top institutional holder at VBIV for having 55.04 Million shares of worth $157.42 Million. And as of September 29, 2020, it was holding 22.74% of the company’s outstanding shares.
The second largest institutional holder is State Street Corporation, which was holding about 18.56 Million shares on September 29, 2020. The number of shares represents firm’s hold over 7.67% of outstanding shares, having a total worth of $53.08 Million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of October 30, 2020, the former fund manager was holding 16285263 shares of worth $38.27 Million or 6.73% of the total outstanding shares. The later fund manager was in possession of 3.47 Million shares on September 29, 2020, making its stake of worth around $9.92 Million in the company or a holder of 1.43% of company’s stock.